UBE2C identified as a key driver in pancreatic cancer via PI3K/Akt/mTOR pathway
UBE2C is overexpressed in pancreatic cancer, promoting progression through the PI3K/Akt/mTOR pathway.
Asset / Drug
Drug and asset intelligence for UBE2C with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.